Is ibrutinib/ibrutinib approved for marketing?

Ibrutinib/Ibrutinib is an innovative small molecule drug whose powerful mechanism of action lies in its ability to act as an irreversible inhibitor of Burton's tyrosine kinase. This product, classified as a targeted covalent drug, has already demonstrated significant activity in the treatment of B-cell malignancies during clinical trials. Ibrutinib was carefully developed by Pharmacyclics Inc. Its research and development results were affirmed by the US Food and Drug Administration (FDA) in November 2013, and it received accelerated approval for the treatment of mantle cell lymphoma (MCL).

In the process of entering the global market, ibrutinib was approved by the European Medicines Agency (EMA) in October 2014, followed by Health Canada in November of the same year, and is sold under the trade name Imbruvica. The layout of ibrutinib in the Chinese market also made important progress in January 2022. It was approved by the National Medical Products Administration and officially launched on the market, sold under the trade name IMBRUVICA.

Over time, the therapeutic scope of ibrutinib has continued to expand. As of August 2017, it has been approved for the treatment of multiple diseases including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). It is worth mentioning that ibrutinib has also become the first drug approved by the FDA for the treatment of cGVHD in children. This breakthrough development will undoubtedly further consolidate its position in the pharmaceutical field.